TCT

Tupan Launches the New Binance Smart Chain TCT

Retrieved on: 
Wednesday, March 6, 2024

NEW YORK, NY, March 06, 2024 (GLOBE NEWSWIRE) -- Recently, Tupan has announced the launch of the new Binance Smart Chain TCT.

Key Points: 
  • NEW YORK, NY, March 06, 2024 (GLOBE NEWSWIRE) -- Recently, Tupan has announced the launch of the new Binance Smart Chain TCT.
  • Bitcoin recently surpassed the $46,000 mark on January 8th, due to recent compliance with the SEC and becoming an ETF and consequently a semi-security.
  • Tupan has started a never-before-seen program to enable its community to farm an Equity token called Tupan Augreen, which represents the shares of the ForestAu Green Investment Fund.
  • To acquire your TCTs before the exchange launch and discover this unique opportunity, join the exclusive list at www.tupan.io/launch

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
Friday, February 23, 2024

BOSTON, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today presented data highlighting its expanded access program (EAP) for FDA-approved allogeneic stem cell therapy Omisirge® (omidubicel-onlv) and Phase 1 data for its allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.

Key Points: 
  • The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.
  • “The data presented at Tandem provide further evidence of the potential of Gamida Cell’s nicotinamide (NAM) technology to develop potentially curative therapies by expanding and enhancing cells,” said Ronit Simantov, MD, Chief Medical and Scientific Officer of Gamida Cell.
  • It allowed for institutional variability in conditioning regimens and supportive care, more closely reflecting the real-world environment.
  • Patients were heavily pretreated with a median of six prior lines of therapy including CAR-T cell therapy and hematopoietic stem cell transplant.

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT

Retrieved on: 
Monday, February 26, 2024

NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT® (American Society for Transplantation and Cellular Therapy and CIBMTR®  (Center for International Blood and Marrow Transplant Research). The presentations reported unprecedented 100% access to potentially curative bone marrow transplant (BMT) and engraftment in evaluable patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and improved long-term survival outcomes greater than 2 years in patients age 65 or older. Patients with r/r AML age 65 and older who also have multiple comorbidities and high-risk cytogenetics have a poor prognosis are seldom offered BMT in current practice due to poor tolerance to induction and conditioning regimens and dismal outcomes. The SIERRA results presented at TCT demonstrate Iomab-B's ability to overcome multiple high-risk features including a TP53 genetic mutation, advanced age and treatment resistant disease. The two oral presentations at this year's TCT mark a total of ten oral presentations of the SIERRA results at various leading transplant, hematology and nuclear medicine conferences in the USA and Europe.

Key Points: 
  • The SIERRA results presented at TCT demonstrate Iomab-B's ability to overcome multiple high-risk features including a TP53 genetic mutation, advanced age and treatment resistant disease.
  • Patients receiving Iomab-B had significantly higher rates of complete remission as well as durable complete remission compared to the control arm.
  • Most importantly, Iomab-B produced improved long-term survival outcomes as only the patients receiving Iomab-B achieved 1-year and 2-year survival.
  • Iomab-B represents an important advancement in transplant conditioning and has the potential to address a significant unmet patient need."

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Retrieved on: 
Friday, February 2, 2024

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).
  • The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.
  • “The EVOQUE system is able to replace the native tricuspid valve, virtually eliminating tricuspid regurgitation in a wide range of patients.
  • The EVOQUE system received CE Mark approval in October 2023, making it the world’s first transcatheter valve replacement therapy to receive regulatory approval to treat TR.

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
Wednesday, January 17, 2024

The hybrid meetings will take place virtually and in person at the Henry B. González Convention Center in San Antonio, Texas, February 21-24.

Key Points: 
  • The hybrid meetings will take place virtually and in person at the Henry B. González Convention Center in San Antonio, Texas, February 21-24.
  • Eligible patients ≥12 years of age received myeloablative conditioning, prophylactic medications and supportive care per individual institutional standards.
  • Omidubicel was approved under the brand name Omisirge® (omidubicel-onlv) by the U.S. FDA in April 2023 for allogeneic stem cell transplant.
  • There were no reported cases of immune effector cell associated neurotoxicity syndrome or graft versus host disease.

CroíValve Announces FDA IDE Approval and Initiation of its Early Feasibility Study

Retrieved on: 
Thursday, January 25, 2024

CroíValve, an Irish-U.S. based medical device company with a novel, transcatheter solution for tricuspid regurgitation (TR), today announced initiation of its Early Feasibility Study (EFS) for the DUO™ Tricuspid Coaptation Valve System, following FDA IDE and CMS approval.

Key Points: 
  • CroíValve, an Irish-U.S. based medical device company with a novel, transcatheter solution for tricuspid regurgitation (TR), today announced initiation of its Early Feasibility Study (EFS) for the DUO™ Tricuspid Coaptation Valve System, following FDA IDE and CMS approval.
  • The device is delivered using percutaneous techniques and is secured using a novel anchor system which leaves the right heart and native valve apparatus untouched.
  • The TANDEM II feasibility study will further develop the clinical validation of this novel technology.
  • "We are delighted to initiate TANDEM II, with strong interest in participation in the study from leading U.S. centers.

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

Retrieved on: 
Tuesday, January 2, 2024

NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that five abstracts have been accepted for presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT® (American Society for Transplantation and Cellular Therapy and CIBMTR®  (Center for International Blood and Marrow Transplant Research) being held February 21 – 24, 2024 in San Antonio, Texas. Two oral presentations will highlight results from the positive Phase 3 SIERRA trial of Iomab-B (131I-Apamistamab), representing 10 oral presentations of the SIERRA results since they were first reported at the 2023 Tandem Meetings.

Key Points: 
  • Two oral presentations will highlight results from the positive Phase 3 SIERRA trial of Iomab-B (131I-Apamistamab), representing 10 oral presentations of the SIERRA results since they were first reported at the 2023 Tandem Meetings.
  • Sandesh Seth, Actinium's Chairman and CEO, said, "We are excited to continue to build recognition for Iomab-B and the SIERRA data with the transplant community at the upcoming TCT meetings.
  • We are highly encouraged by the positive receptivity by the medical and scientific communities to date and look forward to building on this momentum in 2024."
  • The posters will be presented on Thursday, February 22, 2024, from 6:45 – 7:45 PM

JenaValve Featured at the PCR London Valves 2023

Retrieved on: 
Wednesday, December 6, 2023

IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from PCR London Valves 2023, a leading, annual global valve conference.

Key Points: 
  • IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from PCR London Valves 2023, a leading, annual global valve conference.
  • We have seen cases where the severe MR went away after treating the AR," said Professor Andreas Baumbach, Chair for Device Innovation at Queen Mary University of London.
  • "We are still learning a lot about how to best treat AR, but the possibility of Trilogy as a treatment option is encouraging."
  • The 2023 PCR London Valves Course followed the 2023 Transcatheter Cardiovascular Therapeutics (TCT) meeting in October, during which JenaValve's pivotal ALIGN-AR study results were presented.

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Retrieved on: 
Thursday, December 7, 2023

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.
  • Continued progress across these areas will result in more patients diagnosed and treated with Edwards’ repair and replacement technologies, and a significant long-term growth opportunity.
  • Also in 2024, Edwards expects to accelerate its surgical mitral leadership with the global commercialization of its MITRIS RESILIA valve.
  • During the conference, Edwards’ management will reaffirm the company’s 2023 financial guidance and provide guidance for 2024.

Preeminent Additive Manufacturing Event, RAPID + TCT, Returns to West Coast in 2024

Retrieved on: 
Friday, December 1, 2023

North America’s largest additive manufacturing (AM) and industrial 3D-printing event, RAPID + TCT , will return to the West Coast in 2024, as part of SME’s commitment to bring additive manufacturing solutions to key strategic markets in the United States.

Key Points: 
  • North America’s largest additive manufacturing (AM) and industrial 3D-printing event, RAPID + TCT , will return to the West Coast in 2024, as part of SME’s commitment to bring additive manufacturing solutions to key strategic markets in the United States.
  • Renowned for being the original educational forum in AM, the RAPID + TCT 2024 Conference will continue to serve as a knowledge hub.
  • As RAPID + TCT returns to the West Coast in 2024, attendees have the unique opportunity to be part of the evolution of this industry, which is rapidly growing at a rate of 21% through 2027.
  • By fostering commerce, expanding awareness, championing the community and expanding knowledge, RAPID + TCT will propel the AM industry to the next level.